deaths (OS)progression or deaths (PFS)RFS/DFS

mNSCLC - L2 - all population metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - all population

versus docetaxel
avelumab alone vs. docetaxel 1 certainty unassessable-9% certainty unassessable+16%-